









-  Placebo (PBO)
  -  CZP 200 mg Q2W
  -  CZP 400 mg Q4W
- } in PBO controlled studies
-  Double-blind PBO escape to CZP 200 mg Q2W or CZP 400 mg Q4W, with loading dose

-  Dose-blind CZP 200 mg Q2W or CZP 400 mg Q4W
-  Open-label CZP

-  Mandatory blinded PBO escape to active treatment for patients who did not achieve ASAS20 response at both Wk14 and Wk16
-  Mandatory blinded PBO escape to active treatment for patients who failed to achieve  $\geq 10\%$  decrease in both TJC and SJC at both Wk14 and Wk16